Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 20:00 ET | Source: Curiox Biosystems

Curiox Biosystems Signs Master Software License Agreement for Enterprise-Scale Pluto Code Deployment

Curiox Biosystems signs a Master Software License Agreement enabling a global pharma organization to deploy Pluto Code across multiple sites.
April 21, 2026 17:30 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed...
April 21, 2026 17:00 ET | Source: Aktis Oncology Inc.

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentationsData facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in...
April 21, 2026 16:30 ET | Source: Rgenta Therapeutics

Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

WOBURN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA...
April 21, 2026 16:10 ET | Source: CytoDyn Inc.

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc....
April 21, 2026 16:05 ET | Source: PharmAla Biotech

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla files Q2 quarterly financials with increased customer deposits.
April 21, 2026 16:05 ET | Source: Immuneering Corporation

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO...
April 21, 2026 16:05 ET | Source: TELA Bio, Inc.

TELA Bio to Announce First Quarter 2026 Financial Results

MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
April 21, 2026 16:01 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential...
April 21, 2026 16:00 ET | Source: Belite Bio, Inc

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease

Belite expects to complete the new drug application submission in the second quarter of 2026Rolling submission initiated under Breakthrough Therapy Designation SAN DIEGO, April 21, 2026 (GLOBE...